Gu Yong Quan
Beijing, Beijing Municipality, 100053, China
NCT Number: NCT02840786
This is a randomized study comparing stent and plaque excision systems in treatment of Arteriosclerosis occlusive disease of lower extremity (superficial femoral or popliteal artery)
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Beijing, Beijing Municipality, 100053, China
This is a randomized study comparing balloon angioplasty adjunctive stent and plaque excision systems in treatment of Arteriosclerosis occlusive disease of lower extremity (superficial femoral or popliteal artery)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Patients were included if they were de novo stenosis>70% or occlusion of the femoropopliteal at least 18 years of age and referred for claudication (Rutherford-Becker class II-III) or critical limb ischemia (Rutherford-Becker class IV-V). They were excluded if they had one or more of the following: 1. Acute or subacute lower limb ischemia; 2. Severe calcification lesions; 3. Total occlusions lesions more significant than 10 cm or total occlusion lesions with a suspicion of subintimal wire recanalization 4. untreated ipsilateral iliac artery stenosis>70%, or the distal runoff artery <1 root; 5. Previously lower extremity intervention or surgical graft artery bypass; 6. Severe renal insufficiency, creatinine level greater than 2.5 mg/dL; 7. The patient's platelet count is less than 100,000/uL, antiplatelet or anticoagulant contraindications to required medications; 8. Patients with immune system diseases or malignant tumours; 9. ongoing active infection 10. decompensated congestive heart failure or acute coronary syndrome; 11. Unwillingness to return for future follow-up visits
Time frame: 12 months
systolic velocity ratio >2.4 as measured by Duplex ultrasound.
Time frame: 1 day
Technical success was defined as residual stenosis less than 30% by final angiography and/or a flow-limiting dissection.
Time frame: 12 months
it is defined as thefreedom from clinically-driven target lesion revascularization
Time frame: 12 months
Major adverse events included death, index limb ischemia, index limb amputation, clinically driven target lesion revascularization , and significant embolic events, which were defined as causing end-organ damage.
Time frame: 12 months
Limb Salvage is defined as the freedom from secondary major amputation
Xuanwu Hospital, Beijing
Other
Occlusive Disease of Lower Extremity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02685098
Amputation, Arterial Occlusive Disease
Indianapolis, Indiana, United States
View Trial DetailsNCT00526474
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT00617123
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT02514460
Arterial Occlusive Diseases, Arteriosclerosis
Beijing, Beijing Municipality, China
View Trial Details